Quantifying CKD-aP: Tools for Better Care
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
Improving Sleep and Mental Health in Patients with CKD-aP
Leonie Kraft, MD
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
The Critical Interplay: CKD, HF, and Hyperkalemia
Javed Butler, MD
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Potassium Binders: Safety Comes First!
Javed Butler, MD, MPH, MBA
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Jonathan Barratt, MD, PhD
Sydney Tang, MBBS, MD
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Daniel Judge, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
Continuity in Care: Strategies for Managing Growth Hormone Deficiency Through Life’s Stages
Aristides Maniatis, MD
Kari Hosack
Meagan Broeckert
Sam Watson
Modern Neuromodulation: Vagus Nerve Stimulation in Advancing Care for Patients With Drug-Resistant Epilepsy and Treatment-Resistant Depression
Raman Sankar, MD, PhD
Scott Aaronson, MD
Differentiating Neuromodulation Therapies: VNS, DBS, ECT, TMS
VNS: Beyond Seizure Control